REG - Futura Medical PLC - Agreement with Cooper Consumer Health - Correction

Futura MedicalAnnouncement

23/05/2022 10:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220523:nRSW4344Ma&default-theme=true

RNS Number : 4344M  Futura Medical PLC  23 May 2022

 

 

 

23 May 2022

 

 Futura Medical plc

("Futura" or the "Company")

 

RNS Correction - Futura Announces Collaboration with Cooper Consumer Health to
Commercialise MED3000 in EEA, United Kingdom and Switzerland

 

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio
of innovative products based on its proprietary, transdermal DermaSys® drug
delivery technology and currently focused on sexual health and pain, notes
incorrect information in the 'About Cooper Consumer Health boilerplate' in
part of its RNS announcement no: 3503M dated 23 May and restates the relevant
part of the RNS as follows:

About Cooper Consumer Health

Cooper Consumer Health is the European consolidation platform in the
self-medication (OTC) and selfcare field set up by the investment fund
Charterhouse Capital Partners in January 2016. Its mission is to develop and
market more Selfcare solutions, to more people. It believes responsible
Selfcare can contribute to lowering the pressure on national Healthcare
systems and reduce system costs. Today, this platform has a leading position
in France, the Netherlands, Belgium, Italy, Spain, Portugal and Hong Kong. The
'Cooperation Pharmaceutique Francaise' started just outside Paris more than
100 years ago as a cooperative between pharmacists. It acquired Vemedia
Consumer Health in 2016 and Laboratoires Diepharmex in 2019. Meanwhile, the
Group has made several brand acquisitions across Europe, including
Hexomédine, Essaven, and Dacryoserum. The Group's main brands include
Oenobiol, Valdispert, Mag2, Pouxit, Insect Ecran, Audispray and Excilor.

www.cooperconsumerhealth.com (http://www.cooperconsumerhealth.com/)

-ENDS-

For further information please contact:

 

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: investor.relations@futuramedical.com
(mailto:Investor.relations@futuramedical.com)

Tel: +44 (0) 1483 685 670

www.futuramedical.com (http://www.futuramedical.com/)

Nominated Adviser and Sole Broker:

Liberum

Phil Walker/ Richard Lindley/ Ben Cryer/ Kane Collings

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

 

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile/ Zoe Bolt

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 882 9621

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative products based on its proprietary, transdermal
DermaSys® technology. Each DermaSys® formulation is separately patented and
specifically tailored for the selected indication and application, as well as
being optimised for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and consumer
healthcare markets as appropriate. Current therapeutic areas are sexual
health, including erectile dysfunction, and pain relief. Development and
commercialisation strategies are designed to maximise product differentiation
and value creation whilst minimising risk.

MED3000 is Futura's topical gel formulation that is a breakthrough treatment
for erectile dysfunction ("ED") through a unique evaporative mode of action.
Futura has conducted a Phase 3 study using MED3000 in ED, referred to as
"FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised,
double blind, placebo-controlled, home use, parallel group study delivering
highly statistically significant results compared to pre-treatment baseline,
consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3
(internationally accepted clinical trial endpoints in ED) with over 60% of
patients experiencing a clinically meaningful improvement in their ED.
MED3000 also begins to work immediately in some patients, with 60% of patients
seeing onset of their erection within 10 minutes of application. MED3000 is CE
marked in Europe and the UK as a clinically proven topical treatment
for adult men with erectile dysfunction.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(https://www.futuramedical.com/)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPUWWAUPPUBW